Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2019

View Archived Issues

lncRNA 00607 as a tumor suppressor in hepatocellular carcinoma

Intrabone gene therapy with autologous HSCs for transfusion-dependent beta-thalassemia: phase I/II

Collateral undamage: novel arterial growth mechanism underlies neonatal heart regeneration

Mannin Research and McMaster University enter glaucoma drug collaboration

NIAID initiates phase I study of the VRC-HIVRGP096-00-VP HIV vaccine

Myelin can regenerate in MS but mostly doesn't

Recombination, mutation probabilities linked

Immunosuppressive peptide R9-SOCS1-KIR prevents ocular damage in models of autoimmune uveitis

VCN-01 shows promising activity in preclinical models and in phase I study of retinoblastoma

Novo Nordisk initiates phase I pharmacokinetic study of NNC0148-0287sema in type 2 diabetes

New phase I trial investigates use of MK-5475 in moderate to severe PAH

SRPK1 found as therapeutic target for treating acute myeloid leukemia

I-Mab Biopharma begins first-in-human study of TJ-003234

Withyou Biotechnology describes new ACE inhibitors

Destiny Pharma reports data from second phase I safety study of XF-73

FDA approves Imbruvica with obinutuzumab for treatment-naive CLL/SLL

Vaccine targeting mucin-1 designed to function in immunotolerant hosts

Phase III study of Ultomiris in aHUS meets primary objective of complete TMA response

FDA lifts partial clinical hold on phase I studies of MGD-009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...